Evidence-Based Review: Scalp Psoriasis Diagnosis and Treatment Plan

Disclaimer: This review is for educational and informational purposes. It does not constitute personal medical advice. Clinical decisions should remain with your treating dermatologist who has examined you directly.

Preliminary Summary

Question 1: Is the Reclassification to Scalp Psoriasis Clinically Reasonable?

1. Elbow lesions - the elbow is a canonical extensor site for plaque psoriasis, and its involvement is a powerful diagnostic differentiator from seborrheic dermatitis.
2. Dry white/silvery scales - seborrheic dermatitis characteristically produces greasy, yellowish scales. White, dry scaling is typical of psoriasis.
3. Poor response to antifungal/anti-seborrheic therapy - Candid-B contains clotrimazole + betamethasone (an antifungal with steroid). Failure to adequately respond supports a non-fungal etiology, and the lack of response to antifungal treatment is standard clinical reasoning for reconsidering a psoriasis diagnosis.

Question 2: Is Halox-S Lotion (Halobetasol Propionate) an Evidence-Based Treatment for Scalp Psoriasis?

• The AAD-NPF Joint Guidelines (Elmets et al., JAAD 2021;84:432-470) state: "Topical corticosteroids are recommended for the treatment of plaque psoriasis not involving intertriginous areas."
• The scalp psoriasis literature review by Menter et al. (Dermatol Ther 2021, PMC8163911) states: "Topical corticosteroids remain a mainstay treatment in scalp psoriasis, with data supporting safety and efficacy... First-line therapy for patients with any severity of scalp psoriasis with minimal involvement of other sites is topical corticosteroids."
• Halobetasol propionate 0.01% lotion and 0.05% formulations are explicitly listed among super-high-potency corticosteroids in psoriasis treatment tables (Springer Nature reference from web search, 2025).
• A 2025 study published in J Drugs Dermatol (Draelos & Jacobson) evaluated halobetasol propionate 0.01% + tazarotene 0.045% lotion (HP/TAZ) in scalp psoriasis with open-label data showing efficacy in itch reduction, disease clearance, and scaling.

• Superpotent corticosteroids on the scalp can cause skin atrophy with prolonged use, though scalp skin is more resistant to atrophy than facial skin.
• The AAD recommends supervision by a physician for use beyond 12 weeks.
• Use in a lotion/night application mode (as prescribed) is standard practice to limit daily exposure while maximizing efficacy.

Question 3: Is Protar-K (Coal Tar-Based Therapy) Supported by Current Literature?

• The AAD-NPF Joint Guidelines (2021) explicitly state: "Other topical agents like emollients, salicylic acid, anthralin and coal tar can be also used alone or in combination with topical steroids for the treatment of psoriasis."
• The textbook Bolognía Dermatology 5e states: "Coal tar has a range of anti-inflammatory actions and is effective as an antipruritic. Although crude coal tar may be the most effective tar available for the treatment of psoriasis, a distilled and alcohol-derived tar product, liquor carbonis detergens (LCD), is also used." (block 3, line 51)
• Lippincott Illustrated Reviews: Pharmacology confirms: "Keratolytic agents such as coal tar and salicylic acid are effective in localized psoriasis, especially on the scalp. They improve corticosteroid penetration. Coal tar inhibits excessive skin cell proliferation and may also have anti-inflammatory effects." (block 5, line 1575-1579)
• A 2021 RCT in Frontiers in Medicine [PMID 34211988] found that adding 10% LCD (coal tar) to excimer lamp treatment for scalp psoriasis significantly improved outcomes: PSSI75 achieved by 69% of combination group vs. 29% with monotherapy (P<0.05).
• A 2023 narrative review in J Pharm Technology [PMID 37745732] (Chandy, Dao, Feldman et al.) reviewed coal tar alongside newer topicals and found that for a 12-week trial, 58.2% of patients achieved IGA success with coal tar - a respectable figure compared with newer agents.
• The DermNet NZ guidelines list coal tar as a standard topical psoriasis treatment option.

Question 4: Is Maintenance Therapy Once or Twice Weekly Commonly Recommended After Improvement?

• Weekend/intermittent corticosteroid therapy (applying 2 days per week after clearing) is a well-established maintenance strategy in psoriasis. Multiple RCTs have demonstrated that once or twice weekly application of potent topical corticosteroids after clearing significantly delays relapse. The landmark maintenance studies with clobetasol propionate (a superpotent corticosteroid similar to halobetasol) showed that twice-weekly application after clearing extends remission duration substantially.
• The AAD-NPF Guidelines state: "The alternate use of steroids and steroid sparing agents play a critical role in the chronic management of psoriasis."
• The PMC scalp psoriasis review (2021) notes: "Combination therapy consisting of corticosteroids and vitamin D analogs has shown to be an effective long-term maintenance option."
• DermNet NZ guidelines specify: "The ideal target for treatment response is BSA ≤1% maintained at every 6-month assessment interval during maintenance therapy."

Question 5: Is the Statement That Psoriasis Has No Permanent Cure but Can Be Controlled Consistent with Modern Science?

• Bolognía Dermatology 5e and virtually all major dermatology references classify psoriasis as a chronic, relapsing-remitting immune-mediated disease.
• Even the most effective biologics (anti-IL-17, anti-IL-23 agents) that achieve PASI 90 or PASI 100 responses do not cure the disease - relapses occur when treatment is stopped.
• DermNet NZ guidelines explicitly state: "While psoriasis is treatable, there is no cure. Successful management is dependent on the patient understanding the chronic nature of psoriasis."

Question 6: How Strong Is the Evidence for Regular Moisturization in Psoriasis Management?

• A 2025 multicenter clinical trial published in J Drugs Dermatol [PMID 40773615] (Draelos et al., N=46) evaluated adjuvant skincare (cleanser + moisturizer) in plaque psoriasis over 8 weeks. Results showed statistically significant improvements in BSA (9.3→5.1%), target lesion severity (10.9→3.5), physician global assessment (2.7→1.4), and quality of life (DLQI 9.2→2.9), all P<0.05. The authors concluded: "Skincare supported the skin barrier and improved patient outcomes."
• The background of this study states: "Epidermal barrier dysfunction is a key feature of plaque psoriasis. Skincare improves epidermal barrier function and is an increasingly recommended part of psoriasis management."
• The AAD guidelines list emollients as a recommended topical agent in psoriasis management.
• The Mayo Clinic psoriasis treatment resource recommends: "Avoid scratching... apply a nonprescription anti-itch cream or ointment. Stay cool. Wear light clothing." and moisturization is listed as a standard self-care practice.
• The dermatological rationale is sound: psoriatic skin has abnormal epidermal barrier function (reduced ceramide levels, abnormal filaggrin expression), making it more susceptible to dryness and itch. Moisturizers reduce transepidermal water loss, soften scale, and may reduce the itch-scratch cycle.

Question 7: Is Long-Term Intermittent Use of Protar-K (Coal Tar) Considered Safe?

• Coal tar has an excellent long-term topical safety record in clinical use. The Bolognía Dermatology 5e notes that while coal tar has mutagenic potential, it is contraindicated in pregnant or lactating women, but makes no restriction for general long-term use.
• The theoretical carcinogenicity concern comes from industrial/occupational exposure to coal tar at very high doses - this has not been demonstrated to translate to clinical risk with topical preparations at dermatological concentrations.
• A comprehensive review confirms: "There were no serious adverse events for the noncorticosteroid topicals" including coal tar [PMID 37745732].
• Practical adverse effects are cosmetic: odor, staining of clothing/pillowcases, skin irritation, and photosensitivity (avoid sun exposure after application).
• Pediatric dermatology reviews (2024) confirm that coal tar is generally well-tolerated for ongoing use [PMID 37847480].

Question 8: Has Coal Tar Fallen Out of Favor, or Does It Still Have a Legitimate Role?

• Scalp psoriasis maintenance therapy
• Mild-to-moderate disease
• Combined with other topicals (enhances corticosteroid penetration)
• Patients preferring non-steroid options for long-term use
• Cost-effectiveness in resource-limited settings

Question 9: Is This Treatment Plan Broadly Consistent with Evidence-Based Practice?

What is not in the plan (and may be worth discussing with your dermatologist in future):

• Vitamin D analogs (e.g., calcipotriol/calcitriol): Not mentioned, but these are a highly effective first-line option for scalp psoriasis, often combined with topical corticosteroids. A combination corticosteroid + vitamin D analog preparation (e.g., calcipotriol/betamethasone dipropionate) is considered first-line by many guidelines and has strong RCT evidence. This could be relevant if Halox-S monotherapy proves insufficient.
• Keratolytic agents (salicylic acid): Also not mentioned, but the textbook specifically highlights their role in thick-scale scalp psoriasis to enhance penetration of corticosteroids and UV light.
• Scalp-specific formulation: Lotions are appropriate for the scalp (and for different hair types), so the choice of lotion formulations is appropriate.

Key Evidence Sources Consulted

• Bolognía et al., Dermatology 2-Volume Set, 5e - Scalp Psoriasis, Treatment (Textbook)
• Lippincott Illustrated Reviews: Pharmacology - Keratolytic Agents in Psoriasis (Textbook)
• Elmets CA et al. "Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy." J Am Acad Dermatol. 2021;84(2):432-470 (Level A guideline)
• Gisondi P, Bellinato F, Girolomoni G. "Topographic Differential Diagnosis of Chronic Plaque Psoriasis." J Clin Med. 2020 [PMID 33171581]
• Chandy RJ et al. "Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis." J Pharm Technol. 2023 [PMID 37745732]
• Rattanakaemakorn P et al. "308-nm Excimer Lamp vs Combination with 10% Coal Tar in Scalp Psoriasis." Front Med. 2021 [PMID 34211988]
• Draelos Z et al. "Study of Adjuvant Sensitive-Skin Cleansing and Moisturizing Regimen in Plaque Psoriasis." J Drugs Dermatol. 2025 [PMID 40773615]
• "Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations." Dermatol Ther. 2021 [PMC8163911]
• AAD Clinical Guidelines - Psoriasis
• DermNet NZ - Guidelines for the Management of Psoriasis

Summary of Evidence Tiers

• Topical corticosteroids as first-line scalp psoriasis treatment
• Maintenance therapy with reduced frequency after clearance
• Psoriasis as a chronic, incurable immune disease
• Moisturization as an adjunct to reduce barrier dysfunction

• Halobetasol propionate specifically as scalp psoriasis treatment
• Evening application of topical corticosteroid
• Coal tar as adjunct/maintenance for scalp psoriasis
• 30-minute wash-off coal tar protocol

• Optimal maintenance frequency for coal tar specifically (once vs. twice weekly)
• Long-term safety data for halobetasol on the scalp beyond 52 weeks
• Whether coal tar or vitamin D analogs provide superior maintenance to corticosteroid monotherapy
• Optimal formulation of coal tar for scalp (foam vs. shampoo vs. lotion) - limited head-to-head data---

Overall Verdict

Evidence-Based Review: Cleansers, Moisturizers, Bathing Habits, and Water Quality in Psoriasis with Xerosis

Disclaimer: This review is for educational and informational purposes only. It does not constitute personal medical advice. All clinical decisions should remain with your treating dermatologist.

Part 1: Cleansers, Syndets, and the Ideal Cleanser for Psoriasis + Dry Skin

Question 1: Characteristics of an Ideal Long-Term Cleanser for Psoriasis + Dry Skin

"True soaps are composed of long-chain fatty acid alkali salts with a pH between 9 and 10. This alkaline pH raises the pH of the skin following cleansing, resulting in stratum corneum barrier disruption and the resultant feeling of tightness following bathing. Alkalinization of the skin disrupts the natural acid mantle... Recognition of the need to preserve skin pH at 5.4 led to the development of synthetic detergents, known as syndets... Syndet cleansers contain less than 10% soap and are designed with a pH of 5.5-7.0 so as to minimize cutaneous alkalization. Syndets would be the least damaging to the cutaneous barrier in persons with xerosis or any form of dermatitis." (Block 32, lines 3676-3677)

Question 2: Is the Recommendation to Avoid Traditional Alkaline Soaps Supported?

1. pH disruption: Traditional soaps have a pH of 9-10. Normal skin surface pH is 4.5-5.5. Post-soap cleansing transiently raises skin pH by 1-2 units. This:
   • Activates serine proteases (particularly kallikrein 5/7) that degrade corneodesmosomes, accelerating abnormal desquamation
   • Inhibits key barrier-repair enzymes (beta-glucocerebrosidase, sphingomyelinase) that synthesize lamellar body lipids
   • Creates a permissive environment for bacterial colonization (normal flora is adapted to acid pH)
2. Surfactant damage: High-irritancy surfactants (SLS) in traditional soaps solubilize intercellular lipids, increasing transepidermal water loss (TEWL) and disrupting tight junctions.
3. Psoriasis-specific vulnerability: Psoriatic skin has inherently abnormal barrier function (reduced ceramide concentrations, abnormal filaggrin processing), making it especially susceptible to further barrier disruption from alkaline pH.

Question 3: Is Routine Use of Salicylic-Acid Cleansers Advisable in Psoriasis-Associated Xerosis?

• Targeted keratolytic use (scalp, elbows): Salicylic acid 5-10% is a standard keratolytic for psoriatic scale. The Bolognía textbook states: "Salicylic acid 5%-10% has a substantial keratolytic effect and, in the case of scalp psoriasis, salicylic acid can be formulated in an oil or ointment base." This use remains appropriate.
• Routine body cleanser with salicylic acid: Salicylic acid is a beta-hydroxy acid (BHA) with keratolytic, comedolytic, and mild anti-inflammatory properties. At cleanser concentrations (typically 0.5-2%), its wash-off keratolytic effect is modest. However, salicylic acid also has a drying and mildly irritating effect on non-involved skin, and daily whole-body use in someone with xerosis risks worsening dryness in already barrier-compromised skin.
• Paradox for psoriasis: While salicylic acid is appropriate as a targeted treatment on plaques, using it systemically as a routine cleanser risks over-stripping the non-psoriatic skin that is already dry. This can amplify xerosis symptoms without proportionate benefit.
• Salicylic acid systemic absorption concern: The Bolognía textbook also notes: "Application of salicylic acid to localized areas can be done daily, but, for more widespread areas, two to three times per week is preferred. This is to prevent systemic intoxication, especially in infants or those with reduced renal function."

Part 2: Product Reviews

Question 4: Review of Aveeno Calm + Restore Cleanser

Water, Glycerin, Butylene Glycol, Avena Sativa (Oat) Kernel Flour, Polysorbate 20, Poloxamer 188, Zea Mays (Corn) Starch, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Caprylyl Glycol, Phenoxyethanol, Disodium EDTA, Ethylhexylglycerin, Sodium Polyacrylate, Sodium Hydroxide, Chrysanthemum Parthenium (Feverfew) Flower/Leaf/Stem Juice, Sodium Hyaluronate.

• Soap-free, syndet-based: low-irritancy cleansing
• Fragrance-free / no essential oils
• Glycerin + sodium hyaluronate: humectant support
• Oat-based: anti-inflammatory and skin-protectant effects

• Colloidal oatmeal in psoriasis: The Journal of Drugs in Dermatology (Kircik et al.) reports: "An open-label study provides evidence supporting the efficacy and tolerability of a topical, over-the-counter lotion containing oat flour, oat oil and oat extract with avenanthramides as the sole intervention for managing the symptoms of sensitive skin and mild to moderate psoriasis."
• Avenanthramides: These oat-derived polyphenols inhibit nuclear factor κB activation and reduce proinflammatory cytokine and histamine release - mechanisms directly relevant to psoriatic inflammation and itch.
• Aveeno's clinical research base: Aveeno cites 30+ clinical studies across 3,000+ patients supporting their oat-based formulations across dry skin, atopic dermatitis, and psoriasis.
• A 2019 clinical trial [PMID 30207438] evaluated avenanthramide-based cleanser and emollient cream in pediatric atopic dermatitis and xerosis, finding significant improvements in skin hydration and barrier function.

• Syndet/soap-free formulation: Strongly evidence-supported
• Glycerin + hyaluronate humectancy: Strongly evidence-supported
• Oat/avenanthramide anti-inflammatory and barrier properties: Well-supported (FDA skin protectant designation, multiple clinical studies, in vitro mechanistic data)
• Feverfew for redness: Limited clinical evidence (primarily in vitro and small studies)

Question 5: Review of Cebhydra Moisturising Lotion

Purified Water, Butyrospermum Parkii (Shea Butter), Theobroma Cacao (Cocoa) Seed Butter, Cetyl Alcohol, Glycerine, Emulsifying Wax IP, Glyceryl Stearate, PEG-100 Stearate, Cetearyl Olivate, Mangifera Indica (Mango) Seed Butter, Sodium Hyaluronate, Niacinamide, Phenoxyethanol, Sorbitan Olivate, Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer, Isohexadecane, Sodium Hydroxide, Polysorbate 80, Sodium Lauroyl Lactylate, Ethylhexylglycerin, Disodium EDTA, Diazolidinyl Urea, Ceramide 3, Ceramide 6 II, Ceramide 1, Phytosphingosine, Cholesterol, Xanthan Gum, Carbomer, Iodopropynyl Butylcarbamate.

• A 2006 study (referenced in Healthline psoriasis moisturizer review) found that "people with psoriasis have significantly decreased ceramide levels in their skin" - establishing the rationale for ceramide replacement.
• A clinical evaluation published in Cosmoderma found that ceramide + hyaluronate lotion significantly improved skin hydration and barrier function in dry skin, with benefits sustained for 12-24 hours post-application.
• The WHO Essential Medicines List review (2025, WHO/EML) on moisturizers concluded that "the clinical effect appears to be much more well-documented for urea and glycerin than, for example, propylene glycol, lactate, ceramide, and aluminum chlorohydrate" - meaning ceramide evidence is positive but glycerine evidence is more consistently reproducible across studies.
• The textbook Bolognía lists "Dimethicone and ceramides" as a recognized moisturizer category.

• Fragrance-free: appropriate for sensitive/psoriatic skin
• pH 5.5: matches skin's natural acid mantle
• Triple ceramide complex (1, 3, 6 II) + cholesterol + phytosphingosine: directly targets the barrier lipid deficit in psoriasis
• Glycerine + sodium hyaluronate: humectant support
• Shea/cocoa/mango butters: occlusive emolliency
• Niacinamide: anti-inflammatory and barrier-enhancing

Question 6: Are These Products High-Quality Evidence-Based Choices?

Question 7 & 8: What Cleanser and Moisturizer Categories Have the Strongest Scientific Support?

1. Syndet liquid body washes or bars - strongest evidence for barrier preservation vs. true soap
2. Fragrance-free - strong evidence for avoidance in sensitive/inflammatory skin
3. pH 5.0-5.5 - evidence-supported target
4. Glycerin or ceramide additives - supportive evidence for barrier maintenance
5. No SLS as primary surfactant - SLS causes measurable barrier damage; sodium cocoyl isethionate, poloxamer, or glucoside surfactants preferred

1. Ceramide-containing (CeraVe, Cebhydra): replenish psoriasis-depleted barrier lipids
2. Glycerine-based (highest-quality WHO evidence): most consistently documented humectant for dry inflammatory skin
3. Petrolatum-containing (Vaseline, Aquaphor): most effective occlusive (reduces TEWL 99% per textbook); less cosmetically elegant but strongest barrier occlusion
4. Urea-containing (Eucerin Urea, CeraVe Psoriasis Cream): urea is a natural moisturizing factor component; keratolytic at higher concentrations; humectant at lower concentrations

Question 9: Best Evidence-Based Cleanser + Moisturizer Combination (Cost-Irrelevant)

• CeraVe Hydrating Cleanser provides the most extensively studied syndet cleansing profile, with ceramides, hyaluronic acid, and glycerine, at a fragrance-free, mild-surfactant formulation. It is specifically endorsed by the National Eczema Association and has the most robust real-world and clinical study evidence of any OTC cleanser in inflammatory skin conditions.

• The most evidence-supported moisturizer for psoriasis/xerosis combines ceramides 1, 3, and 6 II (replenishing psoriasis-depleted barrier lipids) + hyaluronic acid + glycerine + cholesterol + dimethicone. CeraVe Moisturising Cream is the most cited OTC product in dermatology research for barrier repair in psoriasis and eczema.

Part 3: Bathing Habits - Duration, Temperature, and Water

Question 10: Is Limiting Bathing Duration to Under ~5 Minutes Supported?

• Prolonged water immersion initially hydrates the stratum corneum but then causes swelling, protein disruption (corneocyte over-hydration), and - on drying - leaves the skin in a more dehydrated state than before bathing.
• Water acts as an irritant in excess: prolonged contact disrupts intercellular lipids.
• The Bolognía textbook notes that "excessive use of soap has resulted in dermatologic conditions such as xerotic eczema" and contextualizes over-cleansing as a direct cause of barrier damage.

Question 11: Is Avoiding Hot Water Supported for Psoriasis + Dry Skin?

1. Increases lipid solubilization, removing natural skin oils (sebum, intercellular lipids) more aggressively than warm/cool water
2. Vasodilation and increased blood flow amplify the itch response - histamine release and mast cell degranulation are temperature-sensitive
3. Hot water increases skin permeability and surfactant penetration, worsening barrier damage from any soap/cleanser used
4. Directly triggers itch in psoriasis and atopic dermatitis by activating TRPV1 and TRPA1 channels in sensory neurons

Question 12: Evidence That Hot Water Worsens Barrier Function, TEWL, Itching, Psoriasis Symptoms

Part 4: Hard Water, Chlorine, Chloramine, and Water Filtration

Question 13: Evidence That Hard Water Can Worsen Psoriasis, Xerosis, and Skin Barrier

• Pooled OR 1.28 (95% CI 1.09-1.50) for atopic eczema in children exposed to harder vs. softer water.
• Importantly, two RCTs of water softeners did not show improvement in objective eczema severity (SMD 0.06, 95% CI -0.16 to 0.27), suggesting correlation without proven causation for treatment.
• Hard water increases sodium lauryl sulfate (SLS) deposition on skin post-washing, amplifying barrier damage.

• Each 50 mg/L increase in water hardness was associated with a 3% increased risk of psoriasis.
• Very hard water (>180 mg/L CaCO3) was associated with a 20% higher psoriasis risk vs. soft water.
• Risk was amplified in those with higher genetic psoriasis susceptibility.

1. Ca²⁺ and Mg²⁺ ions react with soap to form insoluble calcium/magnesium stearate ("soap scum") that deposits on skin and causes irritation
2. Hard water increases surfactant deposition (SLS) on skin after washing - SLS residues elevate skin surface pH and solubilize stratum corneum lipids
3. Ca²⁺ concentration in hard water may alter calcium signaling in keratinocytes, impairing barrier repair (Lee SE, Ann Dermatol 2018)
4. Elevated skin surface pH from hard water/soap interaction activates serine proteases that degrade corneodesmosomes

Question 14: Does Reducing Hard-Water Exposure Improve Symptoms?

• Two RCTs of domestic water softeners in children with eczema did not show significant improvement in objective disease severity.
• However, the evidence quality was rated moderate-certainty by GRADE analysis.
• A UK Biobank adult cohort study (PMC9804584) observed that hard water was associated with prevalent and incident eczema in adults (OR 1.12, 95% CI 1.04-1.22 per 50 mg/L increase).

Question 15: Evidence on Chlorine and Chloramine from Municipal Water and Skin-Barrier Health

• Chlorine is a mild oxidant. At typical municipal concentrations (0.5-4 mg/L), it is not strongly irritating to normal skin in brief shower exposure. However, it can contribute to lipid oxidation in skin surface lipids and modestly elevate TEWL.
• Chloramine (used in many municipal systems as a more stable alternative to free chlorine) penetrates skin differently and may have slightly different biological effects, though evidence is minimal.
• A 2024 review (Open Access Research Journal of Biology and Pharmacy) reported that "AD patients showed significantly reduced skin hydration when exposed to bathing water containing chlorine concentrations as low as 1.0 mg/L," citing a study in which stratum corneum water-holding capacity was affected in atopic dermatitis patients at chlorine levels common in municipal supplies.
• Research into the ETIVE (Enquiring About Tolerance) cohort (Perkin et al.) observed an association between domestic water hardness and chlorine exposure and atopic eczema risk, though it was not possible to fully disentangle their independent effects.

Question 16: Do Shower Filters Meaningfully Reduce Chlorine/Chloramine Exposure?

• Chlorine: Carbon-based (activated carbon/KDF) shower filters effectively reduce free chlorine. NSF/ANSI Standard 177 certifies shower filters for chlorine reduction.
• Chloramine: Significantly harder to remove than free chlorine. Standard carbon filters remove chloramine poorly. Vitamin C (ascorbic acid or sodium ascorbate) neutralization is the most effective method for chloramine at typical shower temperatures. Some newer shower filters specifically address chloramine.
• Hard water minerals: Standard shower filters do not remove calcium/magnesium. Hard water mitigation requires whole-house water softeners or under-sink reverse osmosis systems.

Question 17: Evidence That Water Filtration Improves Outcomes in Psoriasis, Eczema, or Dry Skin

• Two RCTs: no significant improvement in objective eczema severity with softened water (SMD 0.06, GRADE: moderate certainty).
• Subjective comfort and parent-reported outcomes were slightly improved in one trial.

Question 18: Best Practice for Bathing Habits in Psoriasis - Summary Synthesis

Overall Verdict on Your Dermatologist's Recommendations

Key Evidence Sources

• Bolognía et al., Dermatology 2-Volume Set, 5e - Chapter 153: Cleansers and Moisturizers (Textbook)
• Jabbar-Lopez ZK et al. "The effect of water hardness on atopic eczema, skin barrier function: A systematic review, meta-analysis." Clin Exp Allergy. 2021 [PMID 33259122] - Level 1
• UK Biobank cohort study: "The association between domestic hard water and eczema in adults" [PMC9804584] - Large observational study
• Danby SG et al. "The effect of water hardness on surfactant deposition after washing and subsequent skin irritation in atopic dermatitis." J Invest Dermatol. 2018 - Mechanistic human study
• Kircik L et al. "Oats in Skincare" - colloidal oatmeal psoriasis evidence summary (J Drugs Dermatol)
• WHO Essential Medicines List review on urea and glycerol moisturizers (2025) - Comparative moisturizer evidence
• Draelos Z et al. "Adjuvant skincare in plaque psoriasis." J Drugs Dermatol. 2025 [PMID 40773615] - Clinical trial
• AAD-NPF Guidelines (Elmets et al., JAAD 2021;84:432-470)---

Quick-Reference Summary of Evidence Tiers Across All 18 Questions

• Avoiding traditional alkaline soaps (Q2)
• Using syndets/pH-balanced cleansers (Q1, Q2)
• Fragrance-free formulations (Q1)
• Regular moisturization in psoriasis (Q6)
• Avoiding hot water in principle (Q11, Q12)
• Ceramide depletion in psoriasis and rationale for ceramide moisturizers (Q5)

• Limiting shower duration to 5-10 minutes (Q10)
• Applying moisturizer within minutes of bathing ("soak and seal") (Q18)
• Avoiding whole-body salicylic acid cleanser in xerosis (Q3)
• Aveeno Calm + Restore as appropriate psoriasis cleanser (Q4)
• Cebhydra as appropriate barrier-repair moisturizer (Q5)
• CeraVe / ceramide-containing moisturizers as best-evidence category (Q7, Q8)

• Hard water as psoriasis aggravator (association established, intervention not proven) (Q13-14)
• Shower filter for chlorine removal improving skin outcomes (Q16-17)
• Chloramine-specific filtration (Q15-16)
• Precise bathing duration thresholds (Q10)